Study Phase 4

A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment527% Female51.5%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-KOR-66Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)37

Supporting Documentation

  • Protocol with Amendments Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol with amendments and synoptic report are available.

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.